P186D

Name *

First Name Last Name
Email *
example@example.com
What best describes your title? *

MD RN/NP PA PharmD Professor Industry
How many years have you been in practice?
How many patients do you typically see each month?
1. Current registry data suggest that which of the following disease-modifying therapies may be associated with more severe COVID-19 disease? *

Dimethyl fumarate Fingolimod Glatiramer acetate Ocrelizumab Teriflunomide
2. In the 2017 McDonald diagnostic criteria, asymptomatic lesions identified by MRI in which of the following locations can be used to document dissemination in space?

I. Periventricular white matter

II. Brainstem

III. Spinal cord

IV. Optic nerve
*

I only I and II I, II, and III All of the above
3. A new class of disease modifying therapy in clinical trials potentially impacts both the adaptive and the innate immune system. Which protein does this drug class target? *

CD20 Interferon receptor Pyridime synthetase Bruton’s Tyrosine Kinase Aldehyde dehydrogenase
4. Which of the following emerging MRI measures has the greatest near-term potential to impact MS diagnosis? *

Cortical lesion visualization at 7 tesla Paramagnetic rim lesion detection at 3 tesla Central vein sign Leptomeningeal gadolinium enhancement
5. The Shared Decision Making Model between clinician and patient results in: *

A one-sided course of action to maintain health and wellness An ongoing interaction between patient and clinician An evidence-based course of treatment based on clinician expertise The best available treatment

6. How confident are you in your responses above? *

	1	2	3	4	5

1 is Not Confident, 5 is Extremely Confident

Complete the following Evaluation to receive your Certificate